Navigation Links
Drug Helps Ease Fat Disorder in HIV Patients
Date:12/5/2007

Tesamorelin shrinks the visceral fat around organs that boosts heart risks

WEDNESDAY, Dec. 5 (HealthDay News) -- An investigational drug may be the first safe, reliable means of easing a disorder that leads to unsightly "humps" of body fat and boosts the heart risks of HIV patients.

People taking the drug tesamorelin for 26 weeks showed a 15 percent decline in dangerous visceral fat accumulating around their organs, as well as an improvement in related heart risk factors. They also reported psychological gains in terms of body image, said researchers reporting in the Dec. 6 issue of the New England Journal of Medicine.

While the long-term safety of tesamorelin remains unanswered, "we are very hopeful about this -- this could be one of the first major therapies in this regard," said the study's senior author, Dr. Steven Grinspoon, an associate professor of medicine at Harvard Medical School.

The study was funded by Theratechnologies, the Canadian company that is developing the drug.

Abnormalities in metabolism and fat deposits ("lipodystrophy") are common in people who take powerful antiretroviral drugs to help suppress HIV. "It's fairly prevalent in over half of the patients," said Grinspoon, who is also director of the Program in Nutritional Metabolism at Massachusetts General Hospital.

For reasons that remain unclear, HIV drug therapy often reduces normal fat levels in the arms and the legs while boosting it in other areas, including unsightly "humps" at the shoulder. The drugs can also shift fat deposition to deep in the abdomen, around the organs. This visceral fat is strongly associated with an increase in blood levels of cholesterol and triglycerides, as well as insulin resistance, which can lead to diabetes.

"All of that conspires to increase the risk of vascular disease," explained Dr. Marc Blackman, associate chief of staff for research and development at the VA Medica
'/>"/>

Copyright©2007 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. New male sling procedure helps prostate cancer survivors who suffer from urinary incontinence
2. Direct Anesthetic Infusion Helps Colorectal Cancer Patients
3. Radiation and drug combo helps boost efficacy of lung cancer treatment
4. New Website Helps Women Be Fit, Sexy and in Control!
5. Childs Flu Shot Helps Whole Family
6. Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit
7. Generic prostate drug helps find high-risk cancers early
8. Tamoxifen Helps Treat Bipolar Disorder
9. Imaging Software Helps Track, Treat Injured Brains
10. GPS-like technology helps pinpoint best methods for moving injured players
11. Brain Defect Helps Drive Fragile X Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Helps Ease Fat Disorder in HIV Patients
(Date:6/3/2015)... June 03, 2015 AvePoint, ... and devices, announced today that it has won the ... and Content. The company was honored among a global ... in innovation and implementation of customer solutions based on ... of the Year Awards – including the 2014 Microsoft ...
(Date:6/3/2015)... Follow us on LinkedIn ... disease treatment on account of their better mode of ... as rheumatoid arthritis. The industry is expected to witness ... molecule drugs to biopharmaceuticals over the coming years. The ... gene therapies, and recombinant proteins has attracted industry players ...
(Date:6/3/2015)... Newark, New Jersey (PRWEB) June 03, 2015 ... chosen by Diversity MBA Magazine as one of the nation’s ... ranked Horizon BCBSNJ No. 6 among its national list of ... ranked Horizon BNCBSNJ as the No. 1 Regional Company. ... been honored by Diversity MBA Magazine for its diverse workplace ...
(Date:6/3/2015)... 03, 2015 Justina Molzon, MS Pharm, ... at DIA’s upcoming Annual Meeting. DIA’s Global Inspire Award ... level of excellence, and commitment to service on a ... Excellence in Service Award that recognizes the “Member of ... DIA volunteer and who has contributed to the advancement ...
(Date:6/3/2015)... Researchers at the University of Western Australia ... the tried-and-true marker mesothelin is the best option available. ... research. Click here to read it now. ... Related Diseases say, even though a mesothelin test can ... to fibulin-3 for identifying mesothelioma. , “Preliminary results ...
Breaking Medicine News(10 mins):Health News:AvePoint Wins 2015 Microsoft Partner of the Year Award for Collaboration and Content 2Health News:AvePoint Wins 2015 Microsoft Partner of the Year Award for Collaboration and Content 3Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 4Health News:Horizon Blue Cross Blue Shield of New Jersey Named a 2015 Best Place for Diverse Managers and Women to Work by Diversity MBA Magazine 2Health News:Former FDA Official and U.S. Public Health Service Officer to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 2Health News:Former FDA Official and U.S. Public Health Service Officer to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 3Health News:Analysis Reveals Gold Standard Mesothelioma Biomarker Still the Best, According to Surviving Mesothelioma 2
... , FRIDAY, Nov. 9 (HealthDay News) -- A drug called ... patients with chronic active gout. , That,s according to a ... who had gout for an average of 13 years. , ... VA Medical Center and University of California, San Diego. , ...
... robots.,It sounds like the theme of a cartoon ... and innovative research being conducted at the University ... cognitive,development of infants with special needs., Two ... professor of,physical therapy, and Sunil Agrawal, professor of ...
... Nov. 9 World Diabetes Day is,November 14, ... celebrating the,successful launch of the 12-Day Stopping Diabetes ... treatments for type 2 diabetes, this,program focuses on ... its patients. Dr. Stuart Seale, medical director ...
... Washington, DC November 9, 2007 Shire plc ... biopharmaceutical company, yesterday announced results of a national survey ... to12 year old childs once-daily Attention Deficit Hyperactivity Disorder ... survey findings report the perceptions of 500 parents of ...
... DAKAR, Senegal -- The National Academy of Sciences and ... of the African Science Academy Development Initiative (ASADI), a ... to provide their nations with evidence-based advice. The ... the value of this advice in informing decisions about ...
... Bulletin Board:,NTRZ), a health science company and a ... that it will release its third quarter financial,results ... Management will host the conference call on ... 2007 third quarter financial results and provide,management updates. ...
Cached Medicine News:Health News:Babies Driving Robots at University 2Health News:Babies Driving Robots at University 3Health News:Babies Driving Robots at University 4Health News:Babies Driving Robots at University 5Health News:Babies Driving Robots at University 6Health News:New Sedona Stopping Diabetes Program 2Health News:Parents survey: Perceptions of the duration of their child's ADHD medication 2Health News:Safe water is theme of African science academies conference in Senegal 2Health News:NutraCea to Host Third Quarter 2007 Financial Results Conference Call November 14 2
(Date:6/3/2015)... NEW YORK , June 3, 2015 ... grow at a CAGR of 10.1% from 2014 to ... market is driven by factors, such as the rising ... and growing technology advancements. However, factors such as lack ... the growth of this market. In ...
(Date:6/3/2015)... 3, 2015  Diomics today announced that Stephen ... has joined the company,s board of directors, effective immediately. ... Project and Clinical Professor at the Lyndon B. Johnson ... at Austin. "Steve brings an incredible ... years as a member of CIA,s clandestine service, including ...
(Date:6/3/2015)... DUBLIN , June 3, 2015  Actavis plc (NYSE: ... that Brent Saunders , CEO and President of Actavis, ... at the Goldman Sachs 36th Annual Global Healthcare Conference in ... Logo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO The presentation ... a.m. Pacific Time at the Terranea Resort, Rancho ...
Breaking Medicine Technology:Dermatology Treatment Devices Market by Type, by Application - Global Forecast to 2019 2Dermatology Treatment Devices Market by Type, by Application - Global Forecast to 2019 3Former CIA Clandestine Service Senior Official Stephen B. Slick joins Diomics Board of Directors 2Actavis to Present at the Goldman Sachs 36th Annual Global Healthcare Conference 2
... ACR70 Results, SOUTH SAN FRANCICSO, Calif., Dec. ... today announced that its oral syk,kinase inhibitor, R788 ... Rheumatoid Arthritis (RA) patients in a,recently completed Phase ... and 150mg po bid (orally, twice daily), showed ...
... BioForm Medical,Inc. (Nasdaq: BFRM ) today announced ... of nasolabial fold treatments,reporting higher patient satisfaction with ... either Juvederm(TM) or Perlane(R). The,results of this study ... of,the Journal of Dermatologic Surgery, a peer-reviewed publication ...
Cached Medicine Technology:Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 2Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 3Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 4Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 5Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study 6Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery 2Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery 3Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery 4Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery 5Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery 6
... Prep Pads prepares the skin for improved ... dry, it leaves a thin film on ... surface and a barrier for natural body ... a dressing or tape. Skin Protectant is ...
... 70% USP and 10% Acetone Alcohol Prep ... antiseptic, anti-infective prior to administering injections. Acetone ... and fats from the skin. They are ... to contain a consistent amount of alcohol ...
Triad Plus Sterile Isopropyl Alcohol 70% USP Prep Pads are medium size. Each package is terminally sterilized, ensuring the safest possible product....
Aplicare's Prep Pads offer convenience, low cost, ease of use. The medium size is appropriate for most applications. Each package is terminally sterilized, ensuring the safest possible product for th...
Medicine Products: